Dose finding safety study of VAL201 in cancer patients

• Research type

  Research Study

• Full title

  A Phase I/II, Dose Escalation Study to Assess the Safety and Tolerability of VAL201 in Patients with Locally Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours

• IRAS ID

  152483

• Contact name

  Rebecca Kristeleit

• Contact email

  r.kristeleit@ucl.ac.uk

• Sponsor organisation

  ValiRx plc

• Eudract number

  2013-004009-25

• Research summary

  An open label Phase I/II dose escalation study to assess the safety, tolerability, the way the body absorbs, distributes, and gets rid of VAL201 in patients with locally advanced or metastatic prostate cancer (spread of cancer cells from the prostate to another part of the body). Initial anti-tumour activity of VAL201 in prostrate cancer patients will be evaluated.
  VAL201 may also be tested in a limited number of patients with other advanced hormonally-driven solid tumours eg fibrosarcoma or ovarian cancer to confirm the maximum tolerated dose of VAL201 and assess initial anti-tumour activity.

• REC name

  Yorkshire & The Humber - Leeds West Research Ethics Committee

• REC reference

  14/YH/1110

• Date of REC Opinion

  9 Oct 2014

• REC opinion

  Further Information Favourable Opinion